We developed DENV and ZIKV FP-VLPs and NS1 proteins to develop a novel, serological algorithm for differentiating ZIKV from DENV infection. Overall, the sensitivity and specificity of the FP-VLP-MAC-ELISA and the NS1-MAC-ELISA were each higher than 80%, with no statistical significance. The accuracy can reach up to 95% with the combination of FP-VLP and NS1 assays

Currently there is no such differential diagnostic kit commercially available. This diagnostic platform is prospective, novel and can reach accuracy higher than 95%. The results have been published in international prestigious journal, including J Clin Microbiol 2019; 57(3):e01506-18; 2015 54(2):412-22 and 2015 Feb;53(2):557-66

1.Development of diagnostic kit to differentiate antibodies from dengue vaccination and infection
2.Development of diagnostic kit to different antibodies from dengue and zika viral infection